BCL2 and B-cell chronic lymphocytic leukemia: Together with B-cell receptor (BCR) signalling, targeted by BCR inhibitor (BCRi) drugs such as idelalisib and ibrutinib, Bcl-2 represents an important element in CLL pathogenesis.